|
Market Cap | 256.05M | EPS (ttm) | 0.03 |
P/E | 177.29 | EPS this Y | 29.76% |
Forward P/E | 8.73 | EPS next Y | 40.37% |
PEG | - | EPS past 5Y | -18.66% |
P/S | 1.30 | EPS next 5Y | - |
P/B | 3.07 | EPS Q/Q | 51700.00% |
Dividend | - | Sales Q/Q | 3.94% |
Insider Own | 77.67% | Inst Own | 24.68% |
Insider Trans | 0.00% | Inst Trans | 0.42% |
Short Float | 15.93% | Earnings | May 10/b |
Analyst Recom | 2.50 | Target Price | 6.00 |
Avg Volume | 67.60K | 52W Range | 4.50 - 9.94 |
|
|
Today | Downgrade |
Leerink Partners |
Outperform → Market Perform |
$8.25 → $5 |
|
|
AirSculpt Technologies, Inc. is a fat removal treatment under its brand, Elite Body Sculpture.. It provides custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure, producing dramatic results. The company was founded by Aaron J. Rollins in 2012 and is headquartered in Miami Beach, FL. |
|
|
|
Market Cap | 58.03M | EPS (ttm) | -0.44 |
P/E | - | EPS this Y | -12.73% |
Forward P/E | - | EPS next Y | 23.89% |
PEG | - | EPS past 5Y | 62.58% |
P/S | 1.29 | EPS next 5Y | - |
P/B | 2.47 | EPS Q/Q | 38.77% |
Dividend | - | Sales Q/Q | 44.90% |
Insider Own | 10.23% | Inst Own | 74.70% |
Insider Trans | 27.11% | Inst Trans | 0.68% |
Short Float | 3.84% | Earnings | May 13/a |
Analyst Recom | 1.67 | Target Price | 6.58 |
Avg Volume | 385.62K | 52W Range | 2.22 - 6.25 |
|
|
Today | Downgrade |
Evercore ISI |
Outperform → In-line |
$5 → $1.50 |
Today | Downgrade |
Maxim Group |
Buy → Hold |
$5 |
|
|
Augmedix, Inc. engages in the development of software that converts natural clinician-patient conversations into medical documentation. It offers live support including referrals, orders, and reminders that allow clinicians to focus on patient care. The company was founded by Ian Shakil in 2012 and is headquartered in San Francisco, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Shakil Ian | CHIEF STRATEGY OFFICER | Apr 15 '24 | Option Exercise | 0.86 | 500 | 430 | 3,500 | Apr 16 09:07 PM | Shakil Ian | CHIEF STRATEGY OFFICER | Apr 15 '24 | Sale | 3.80 | 500 | 1,900 | 3,000 | Apr 16 09:07 PM | Shakil Ian | CHIEF STRATEGY OFFICER | Apr 12 '24 | Option Exercise | 0.86 | 19,544 | 16,808 | 22,544 | Apr 15 09:15 PM | Shakil Ian | CHIEF STRATEGY OFFICER | Apr 12 '24 | Sale | 3.82 | 19,544 | 74,590 | 3,000 | Apr 15 09:15 PM | Shakil Ian | CHIEF STRATEGY OFFICER | Apr 11 '24 | Option Exercise | 0.86 | 24,778 | 21,309 | 27,778 | Apr 11 08:30 PM |
|
|
|
|
Market Cap | 55.71M | EPS (ttm) | -1.29 |
P/E | - | EPS this Y | 82.01% |
Forward P/E | - | EPS next Y | 25.79% |
PEG | - | EPS past 5Y | -184.24% |
P/S | 0.10 | EPS next 5Y | - |
P/B | 0.22 | EPS Q/Q | 82.49% |
Dividend | - | Sales Q/Q | 10.38% |
Insider Own | 10.83% | Inst Own | 19.93% |
Insider Trans | 2.21% | Inst Trans | -9.15% |
Short Float | 4.92% | Earnings | May 15/a |
Analyst Recom | 1.67 | Target Price | 12.92 |
Avg Volume | 495.69K | 52W Range | 1.61 - 11.42 |
|
|
Today | Downgrade |
Jefferies |
Buy → Hold |
$11.50 → $3.75 |
|
|
Inotiv, Inc. is a pharmaceutical development company, which engages in the provision of nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to academia and government clients. It operates under the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. The DSA segment focuses on drug discovery and development services. The RMS segment includes commercial production and selling research models, diets, bedding, and bioproducts. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Beattie John Gregory | Chief Operating Officer | Dec 14 '23 | Buy | 3.12 | 47,966 | 149,836 | 111,761 | Dec 15 05:33 PM | Garrett Michael | Chief Commercial Officer | Dec 14 '23 | Buy | 2.83 | 5,000 | 14,145 | 16,467 | Dec 15 05:33 PM |
|
|
| |
|
Market Cap | 5.70B | EPS (ttm) | 38.04 |
P/E | 1.96 | EPS this Y | 34.70% |
Forward P/E | 4.08 | EPS next Y | 5.74% |
PEG | - | EPS past 5Y | -12.54% |
P/S | 1.59 | EPS next 5Y | - |
P/B | 0.59 | EPS Q/Q | 154.88% |
Dividend | 3.75% | Sales Q/Q | 57.01% |
Insider Own | 1.49% | Inst Own | 91.68% |
Insider Trans | -1.26% | Inst Trans | -1.78% |
Short Float | 4.87% | Earnings | May 08/a |
Analyst Recom | 3.00 | Target Price | 73.25 |
Avg Volume | 890.53K | 52W Range | 27.24 - 81.52 |
|
|
Today | Downgrade |
Keefe Bruyette |
Outperform → Mkt Perform |
|
|
|
Jackson Financial, Inc. operates as an investment holding company. The firm operates through the following segments: Retail Annuities, Institutional Products, and Closed Life and Annuity Blocks. The Retail Annuities segment offers various retirement income and savings products, including variable, fixed index, fixed, and immediate payout annuities, as well as registered index-linked annuities and lifetime income solutions. The Institutional Products segment provides traditional guaranteed investment contracts, funding agreements consisting of agreements issued in conjunction with its participation in the U.S. federal home loan bank program, and medium-term funding agreement-backed notes. The Closed Life and Annuity Blocks segment offers various protection products, such as whole life, universal life, variable universal life, and term life insurance products, as well as fixed, fixed index, and payout annuities. This segment also provides a block of group payout annuities. The firm also offers investment management services. The company was founded in 1961 and is headquartered in Lansing, MI. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Ganguly Devkumar Dilip | EVP & Chief Operating Officer | May 10 '24 | Sale | 75.67 | 13,000 | 983,710 | 93,405 | May 13 04:11 PM | Raub Christopher | EVP and Chief Risk Officer | Apr 04 '24 | Option Exercise | 0.00 | 8,497 | 0 | 29,468 | Apr 08 03:01 PM | Raub Christopher | EVP and Chief Risk Officer | Mar 10 '24 | Option Exercise | 0.00 | 5,709 | 0 | 20,388 | Mar 12 04:34 PM | Kirkland Derek G | Director | Mar 04 '24 | Buy | 55.67 | 3,500 | 194,845 | 37,726 | Mar 05 04:12 PM | Romine Scott | President and CEO, JNLD | Dec 14 '23 | Sale | 50.97 | 5,000 | 254,850 | 67,429 | Dec 18 04:36 PM |
|
|
|
|
Market Cap | 143.05M | EPS (ttm) | -3.07 |
P/E | - | EPS this Y | 4.62% |
Forward P/E | - | EPS next Y | 20.74% |
PEG | - | EPS past 5Y | -12.39% |
P/S | - | EPS next 5Y | - |
P/B | 1.09 | EPS Q/Q | -3.35% |
Dividend | - | Sales Q/Q | - |
Insider Own | 11.99% | Inst Own | 90.16% |
Insider Trans | -0.12% | Inst Trans | -1.64% |
Short Float | 10.52% | Earnings | May 09/b |
Analyst Recom | 2.33 | Target Price | 18.75 |
Avg Volume | 1.51M | 52W Range | 4.18 - 27.35 |
|
|
Today | Downgrade |
Wolfe Research |
Outperform → Peer Perform |
|
|
|
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Brockstedt Dirk G. | CHIEF SCIENTIFIC OFFICER | Jan 05 '24 | Sale | 22.78 | 898 | 20,456 | 27,820 | Jan 08 05:50 PM | Brockstedt Dirk G. | Chief Scientific Officer | Dec 29 '23 | Option Exercise | 6.18 | 8,000 | 49,440 | 27,070 | Jan 02 04:29 PM | HO WILLIAM | Chief Medical Officer | Dec 21 '23 | Sale | 21.68 | 2,500 | 54,200 | 15,020 | Dec 22 02:31 PM | HO WILLIAM | Chief Medical Officer | Nov 28 '23 | Sale | 13.72 | 1,500 | 20,580 | 17,520 | Nov 29 02:29 PM | HO WILLIAM | Chief Medical Officer | Oct 03 '23 | Sale | 15.77 | 2,500 | 39,425 | 18,789 | Oct 04 06:29 PM |
|
|
| |
|
Market Cap | 69.21M | EPS (ttm) | - |
P/E | - | EPS this Y | -401.04% |
Forward P/E | - | EPS next Y | 93.77% |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 0.96 | EPS Q/Q | - |
Dividend | - | Sales Q/Q | - |
Insider Own | 92.25% | Inst Own | 8.46% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 8.62% | Earnings | May 13/a |
Analyst Recom | 3.00 | Target Price | 3.75 |
Avg Volume | 93.49K | 52W Range | 2.15 - 7.99 |
|
|
Today | Downgrade |
ROTH MKM |
Buy → Neutral |
$9 → $3.50 |
Today | Downgrade |
Craig Hallum |
Buy → Hold |
|
|
|
Shimmick Corp. engages in the provision of water and other critical infrastructure solutions. The company was founded in 1990 and is headquartered in Irvine, CA. |
|
|